Latest news
Debiopharm S.A. announces a patent application on a hydrosoluble prodrug of cyclosporin A
Debiopharm S.A. licenses-in new technology to turn injectable macromolecular drugs into oral formulations
Media Alert: successful registration after shortest ever review by the FDA of Eloxatin
Dyax Corp. and Debiopharm S.A. report successful results of phase IIA clinical trial with DX-890 for cystic fibrosis
Debiopharm S.A. inaugurates a new State-of-the-Art Galenic Unit in Gland, Switzerland
H3 Pharma announces promising developments for the treatment of Alzheimer´s disease
Debiopharm S.A. reports study revealing that EPI-HNE4 offers protection against acute lung injury
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.